{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:23:02Z","timestamp":1783984982219,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T00:00:00Z","timestamp":1466985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T00:00:00Z","timestamp":1466985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,2,2]]},"DOI":"10.1038\/onc.2016.226","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T10:14:52Z","timestamp":1467022492000},"page":"714-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells"],"prefix":"10.1038","volume":"36","author":[{"given":"R","family":"Eguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,27]]},"reference":[{"key":"BFonc2016226_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA . Malignant mesothelioma. Lancet 2005; 366: 397\u2013408.","journal-title":"Lancet"},{"key":"BFonc2016226_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA, Kindler HL . Malignant pleural mesothelioma. J Clin Oncol 2009; 27: 2081\u20132090.","journal-title":"J Clin Oncol"},{"key":"BFonc2016226_CR3","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/S0140-6736(08)60703-5","volume":"371","author":"NJ Vogelzang","year":"2008","unstructured":"Vogelzang NJ . Chemotherapy for malignant pleural mesothelioma. Lancet 2008; 371: 1640\u20131642.","journal-title":"Lancet"},{"key":"BFonc2016226_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11912-005-0048-3","volume":"7","author":"RK Goudar","year":"2005","unstructured":"Goudar RK . New therapeutic options for mesothelioma. Curr Oncol Rep 2005; 7: 260\u2013265.","journal-title":"Curr Oncol Rep"},{"key":"BFonc2016226_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636\u20132644.","journal-title":"J Clin Oncol"},{"key":"BFonc2016226_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","volume":"85","author":"JG Edwards","year":"2001","unstructured":"Edwards JG, Cox G, Andi A, Jones JL, Walker RA, Waller DA et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 2001; 85: 863\u2013868.","journal-title":"Br J Cancer"},{"key":"BFonc2016226_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D","volume":"182","author":"S Kumar-Singh","year":"1997","unstructured":"Kumar-Singh S, Vermeulen PB, Weyler J, Segers K, Weyn B, Van Daele A et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997; 182: 211\u2013216.","journal-title":"J Pathol"},{"key":"BFonc2016226_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","volume":"81","author":"Y Ohta","year":"1999","unstructured":"Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999; 81: 54\u201361.","journal-title":"Br J Cancer"},{"key":"BFonc2016226_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","volume":"86","author":"D Hanahan","year":"1996","unstructured":"Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353\u2013364.","journal-title":"Cell"},{"key":"BFonc2016226_CR10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nrclinonc.2011.21","volume":"8","author":"JM Ebos","year":"2011","unstructured":"Ebos JM, Kerbel RS . Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 210\u2013221.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFonc2016226_CR11","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak HF . Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368\u20134380.","journal-title":"J Clin Oncol"},{"key":"BFonc2016226_CR12","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1172\/JCI70212","volume":"123","author":"J Welti","year":"2013","unstructured":"Welti J, Loges S, Dimmeler S, Carmeliet P . Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013; 123: 3190\u20133200.","journal-title":"J Clin Invest"},{"key":"BFonc2016226_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","volume":"77","author":"JE Dowell","year":"2012","unstructured":"Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J et al. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer (Amsterdam, Netherlands) 2012; 77: 567\u2013571.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"BFonc2016226_CR14","first-page":"1289","volume":"37","author":"R Eguchi","year":"2010","unstructured":"Eguchi R, Fujimori Y, Ohta T, Kunimasa K, Nakano T . Calpain is involved in cisplatin-induced endothelial injury in an in vitro three-dimensional blood vessel model. Int J Oncol 2010; 37: 1289\u20131296.","journal-title":"Int J Oncol"},{"key":"BFonc2016226_CR15","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS . Tumor angiogenesis. N Engl J Med 2008; 358: 2039\u20132049.","journal-title":"N Engl J Med"},{"key":"BFonc2016226_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0065-230X(10)06003-3","volume":"106","author":"EC Keeley","year":"2010","unstructured":"Keeley EC, Mehrad B, Strieter RM . CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res 2010; 106: 91\u2013111.","journal-title":"Adv Cancer Res"},{"key":"BFonc2016226_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/bph.12537","volume":"171","author":"K Kadomatsu","year":"2014","unstructured":"Kadomatsu K, Bencsik P, Gorbe A, Csonka C, Sakamoto K, Kishida S et al. Therapeutic potential of midkine in cardiovascular disease. Br J Pharmacol 2014; 171: 936\u2013944.","journal-title":"Br J Pharmacol"},{"key":"BFonc2016226_CR18","first-page":"296","volume":"1836","author":"G Palma","year":"2013","unstructured":"Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M et al. Interleukin 18: friend or foe in cancer. Biochim Biophys Acta 2013; 1836: 296\u2013303.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2016226_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","volume":"38","author":"Y Guo","year":"2012","unstructured":"Guo Y, Xu F, Lu T, Duan Z, Zhang Z . Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38: 904\u2013910.","journal-title":"Cancer Treat Rev"},{"key":"BFonc2016226_CR20","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.2217\/fon.14.194","volume":"10","author":"C Bao","year":"2014","unstructured":"Bao C, Wang J, Ma W, Wang X, Cheng Y . HDGF: a novel jack-of-all-trades in cancer. Fut Oncol (London, England) 2014; 10: 2675\u20132685.","journal-title":"Fut Oncol (London, England)"},{"key":"BFonc2016226_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/OTT.S58622","volume":"7","author":"T Koltai","year":"2014","unstructured":"Koltai T . Clusterin: a key player in cancer chemoresistance and its inhibition. OncoTargets Ther 2014; 7: 447\u2013456.","journal-title":"OncoTargets Ther"},{"key":"BFonc2016226_CR22","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s00109-003-0474-3","volume":"81","author":"Z He","year":"2003","unstructured":"He Z, Bateman A . Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berlin, Germany) 2003; 81: 600\u2013612.","journal-title":"J Mol Med (Berlin, Germany)"},{"key":"BFonc2016226_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0006-291X(92)92349-3","volume":"188","author":"V Bhandari","year":"1992","unstructured":"Bhandari V, Bateman A . Structure and chromosomal location of the human granulin gene. Biochem Biophys Res Commun 1992; 188: 57\u201363.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFonc2016226_CR24","doi-asserted-by":"crossref","first-page":"10863","DOI":"10.1016\/S0021-9258(18)82064-6","volume":"268","author":"J Zhou","year":"1993","unstructured":"Zhou J, Gao G, Crabb JW, Serrero G . Purification of an autocrine growth factor homologous with mouse epithelin precursor from a highly tumorigenic cell line. J Biol Chem 1993; 268: 10863\u201310869.","journal-title":"J Biol Chem"},{"key":"BFonc2016226_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nm816","volume":"9","author":"Z He","year":"2003","unstructured":"He Z, Ong CH, Halper J, Bateman A . Progranulin is a mediator of the wound response. Nat Med 2003; 9: 225\u2013229.","journal-title":"Nat Med"},{"key":"BFonc2016226_CR26","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/hep.22191","volume":"47","author":"JC Ho","year":"2008","unstructured":"Ho JC, Ip YC, Cheung ST, Lee YT, Chan KF, Wong SY et al. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology (Baltimore, MD) 2008; 47: 1524\u20131532.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"BFonc2016226_CR27","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1158\/1078-0432.CCR-1123-03","volume":"10","author":"CX Pan","year":"2004","unstructured":"Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L et al. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Clin Cancer Res 2004; 10: 1333\u20131337.","journal-title":"Clin Cancer Res"},{"key":"BFonc2016226_CR28","first-page":"3085","volume":"5","author":"D Yang","year":"2015","unstructured":"Yang D, Wang LL, Dong TT, Shen YH, Guo XS, Liu CY et al. Progranulin promotes colorectal cancer proliferation and angiogenesis through TNFR2\/Akt and ERK signaling pathways. Am J Cancer Res 2015; 5: 3085\u20133097.","journal-title":"Am J Cancer Res"},{"key":"BFonc2016226_CR29","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/cncr.20219","volume":"100","author":"B Davidson","year":"2004","unstructured":"Davidson B, Alejandro E, Florenes VA, Goderstad JM, Risberg B, Kristensen GB et al. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma. Cancer 2004; 100: 2139\u20132147.","journal-title":"Cancer"},{"key":"BFonc2016226_CR30","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1165\/rcmb.2003-0266OC","volume":"30","author":"X Sun","year":"2004","unstructured":"Sun X, Gulyas M, Hjerpe A . Mesothelial differentiation as reflected by differential gene expression. Am J Resp Cell Mol Biol 2004; 30: 510\u2013518.","journal-title":"Am J Resp Cell Mol Biol"},{"key":"BFonc2016226_CR31","doi-asserted-by":"publisher","first-page":"e64989","DOI":"10.1371\/journal.pone.0064989","volume":"8","author":"H Toh","year":"2013","unstructured":"Toh H, Cao M, Daniels E, Bateman A . Expression of the growth factor progranulin in endothelial cells influences growth and development of blood vessels: a novel mouse model. PLoS One 2013; 8: e64989.","journal-title":"PLoS One"},{"key":"BFonc2016226_CR32","doi-asserted-by":"publisher","first-page":"32298","DOI":"10.1074\/jbc.R112.399170","volume":"287","author":"B Cenik","year":"2012","unstructured":"Cenik B, Sephton CF, Kutluk Cenik B, Herz J, Yu G . Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration. J Biol Chem 2012; 287: 32298\u201332306.","journal-title":"J Biol Chem"},{"key":"BFonc2016226_CR33","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/humu.20785","volume":"29","author":"I Gijselinck","year":"2008","unstructured":"Gijselinck I, Van Broeckhoven C, Cruts M . Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. Hum Mutat 2008; 29: 1373\u20131386.","journal-title":"Hum Mutat"},{"key":"BFonc2016226_CR34","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1016\/j.neurobiolaging.2013.05.004","volume":"34","author":"CM Karch","year":"2013","unstructured":"Karch CM, Jeng AT, Skorupa T, Cruchaga C, Goate AM . Novel progranulin variants do not disrupt progranulin secretion and cleavage. Neurobiol Aging 2013; 34: 2538\u20132540.","journal-title":"Neurobiol Aging"},{"key":"BFonc2016226_CR35","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1002\/pmic.200800055","volume":"8","author":"R Eguchi","year":"2008","unstructured":"Eguchi R, Naitou H, Kunimasa K, Ayuzawa R, Fujimori Y, Ohashi N et al. Proteomic analysis of hypoxia-induced tube breakdown of an in vitro capillary model composed of HUVECs: potential role of p38-regulated reduction of HSP27. Proteomics 2008; 8: 2897\u20132906.","journal-title":"Proteomics"},{"key":"BFonc2016226_CR36","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cellsig.2013.05.008","volume":"25","author":"R Eguchi","year":"2013","unstructured":"Eguchi R, Kubo S, Ohta T, Kunimasa K, Okada M, Tamaki H et al. FK506 induces endothelial dysfunction through attenuation of Akt and ERK1\/2 independently of calcineurin inhibition and the caspase pathway. Cell Signal 2013; 25: 1731\u20131738.","journal-title":"Cell Signal"},{"key":"BFonc2016226_CR37","doi-asserted-by":"publisher","first-page":"7467","DOI":"10.1074\/jbc.M112.446401","volume":"288","author":"M Gourlaouen","year":"2013","unstructured":"Gourlaouen M, Welti JC, Vasudev NS, Reynolds AR . Essential role for endocytosis in the growth factor-stimulated activation of ERK1\/2 in endothelial cells. J Biol Chem 2013; 288: 7467\u20137480.","journal-title":"J Biol Chem"},{"key":"BFonc2016226_CR38","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/carcin\/bgs109","volume":"33","author":"R Eguchi","year":"2012","unstructured":"Eguchi R, Kubo S, Takeda H, Ohta T, Tabata C, Ogawa H et al. Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells. Carcinogenesis 2012; 33: 969\u2013975.","journal-title":"Carcinogenesis"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2016226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016226","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2016226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T21:03:55Z","timestamp":1647896635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2016226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,27]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,2,2]]}},"alternative-id":["BFonc2016226"],"URL":"https:\/\/doi.org\/10.1038\/onc.2016.226","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,27]]},"assertion":[{"value":"18 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}